Literature DB >> 20117839

Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Sheri Tinnell Dorsam1, Emilie Vomhof-Dekrey, Rebecca J Hermann, Jodie S Haring, Travis Van der Steen, Erich Wilkerson, Goran Boskovic, James Denvir, Yulia Dementieva, Donald Primerano, Glenn Paul Dorsam.   

Abstract

More than 40 years after the discovery of vasoactive intestinal peptide (VIP), its transcriptome in the immune system has still not been completely elucidated. In an attempt to understand the biological role of this neuropeptide in immunity, we chose CD4 T cells as a cellular system. Agilent Mouse Whole Genome microarrays were hybridized with fluorescently labeled total RNA isolated from resting CD4 T cells cultured +/-10(-7)M VIP for 5h or PMA/ionomycin activated CD4 T cells cultured +/-10(-7)M VIP for 5h. These VIP-regulated transcriptomes were analyzed by Significance Analysis of Microarrays (SAM) and Ingenuity Pathway Analysis (IPA) software to identify relevant signaling pathways modulated by VIP in the absence and presence of T cell activation. In resting CD4 T cells, VIP-modulated 368 genes, ranging from 3.49 to -4.78-fold. In the PMA/ionomycin activated CD4 T cells, 326 gene expression levels were changed by VIP, ranging from 2.94 to -1.66-fold. IPA analysis revealed that VIP exposure alters cellular function through EGFR signaling in resting CD4 T cells, and modulates immediate early genes, Fos and CREM/ICER, in activated CD4 T cells. These gene expression changes are suggested to explain at a molecular level how VIP can regulate T cell homing to the gut and induce regulatory T cell generation. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117839      PMCID: PMC2834953          DOI: 10.1016/j.molimm.2010.01.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  75 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 2.  The significance of vasoactive intestinal peptide in immunomodulation.

Authors:  Mario Delgado; David Pozo; Doina Ganea
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

3.  Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease.

Authors:  M Delgado; C Abad; C Martinez; J Leceta; R P Gomariz
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

Authors:  Catalina Abad; Carmen Martinez; Maria G Juarranz; Alicia Arranz; Javier Leceta; Mario Delgado; Rosa P Gomariz
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

5.  Motor domain-dependent localization of myo1b (myr-1).

Authors:  N Tang; E M Ostap
Journal:  Curr Biol       Date:  2001-07-24       Impact factor: 10.834

6.  The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement.

Authors:  S L Sabo; A F Ikin; J D Buxbaum; P Greengard
Journal:  J Cell Biol       Date:  2001-06-25       Impact factor: 10.539

7.  VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells.

Authors:  Xiuju Jiang; Huie Jing; Doina Ganea
Journal:  J Neuroimmunol       Date:  2002-12       Impact factor: 3.478

8.  The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.

Authors:  Zhibo Yang; Rozita Bagheri-Yarmand; Rui-An Wang; Liana Adam; Vali Vassiliki Papadimitrakopoulou; Gary L Clayman; Adel El-Naggar; Reuben Lotan; Christopher J Barnes; Waun Ki Hong; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

9.  c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide.

Authors:  Julia Voice; Samantha Donnelly; Glenn Dorsam; Gregory Dolganov; Sudhir Paul; Edward J Goetzl
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

10.  Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.

Authors:  Hiroshi Keino; Takeshi Kezuka; Masaru Takeuchi; Naoyuki Yamakawa; Takaaki Hattori; Masahiko Usui
Journal:  Arch Ophthalmol       Date:  2004-08
View more
  10 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

2.  Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.

Authors:  Emilie E Vomhof-DeKrey; Ashley R Sandy; Jarrett J Failing; Rebecca J Hermann; Scott A Hoselton; Jane M Schuh; Abby J Weldon; Kimberly J Payne; Glenn P Dorsam
Journal:  Peptides       Date:  2011-08-22       Impact factor: 3.750

3.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

4.  Toll-like receptor 5 engagement induces interleukin-17C expression in intestinal epithelial cells.

Authors:  Eunok Im; Jane Jung; Sang Hoon Rhee
Journal:  J Interferon Cytokine Res       Date:  2012-09-20       Impact factor: 2.607

5.  Gene expression profiling and network analysis of peripheral blood monocytes in a chronic model of allergic asthma.

Authors:  Glenn P Dorsam; Scott A Hoselton; Ashley R Sandy; Amali E Samarasinghe; Emilie E Vomhof-Dekrey; Sheri T Dorsam; Jane M Schuh
Journal:  Microbiol Immunol       Date:  2010-09       Impact factor: 1.955

6.  Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections.

Authors:  Emilie E Vomhof-DeKrey; Jodie S Haring; Glenn P Dorsam
Journal:  J Neuroimmunol       Date:  2011-03-10       Impact factor: 3.478

7.  Gene expression profiling in gastric mucosa from Helicobacter pylori-infected and uninfected patients undergoing chronic superficial gastritis.

Authors:  Ze-Min Yang; Wei-Wen Chen; Ying-Fang Wang
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

8.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Authors:  Catalina Abad; Bhavaani Jayaram; Laurine Becquet; Yuqi Wang; M Sue O'Dorisio; James A Waschek; Yossan-Var Tan
Journal:  J Neuroinflammation       Date:  2016-06-29       Impact factor: 8.322

9.  The Gut's Little Brain in Control of Intestinal Immunity.

Authors:  Wouter J de Jonge
Journal:  ISRN Gastroenterol       Date:  2013-04-04

10.  Is gastrectomy-induced high turnover of bone with hyperosteoidosis and increase of mineralization a typical osteomalacia?

Authors:  Takashi Ueyama; Yuta Yamamoto; Kazuki Ueda; Aiji Yajima; Yoshimasa Maeda; Yasunobu Yamashita; Takao Ito; Yoshihiro Tsuruo; Masao Ichinose
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.